2. UroToday Home
  3. Trials in Progress
  4. PROMISE PCCTC Study: Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

PROMISE PCCTC Trial Videos

Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang

Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang

Details
Clara Hwang shares an overview of her ASCO 2022 poster session presentation with Alicia Morgans. Dr. Hwang explains how the research was motivated by the known disparities in Black versus white men regarding prostate cancer diagnosis and prognosis. She then describes how this study explored these disparities within the prostate cancer precision medicine space. Biographies: Clara Hwang, MD, Medical...
Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng

Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng

Details
Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director, Seattle...